 Protein Kinase Inhibitors
"Protein Kinase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that inhibit PROTEIN KINASES.
| Descriptor ID |
D047428
|
| MeSH Number(s) |
D27.505.519.389.755
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Protein Kinase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Protein Kinase Inhibitors".
This graph shows the total number of publications written about "Protein Kinase Inhibitors" by people in this website by year, and whether "Protein Kinase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 2 | 2 | | 1997 | 0 | 1 | 1 | | 1999 | 0 | 1 | 1 | | 2003 | 0 | 1 | 1 | | 2004 | 0 | 4 | 4 | | 2005 | 3 | 3 | 6 | | 2006 | 6 | 7 | 13 | | 2007 | 10 | 4 | 14 | | 2008 | 6 | 10 | 16 | | 2009 | 6 | 6 | 12 | | 2010 | 20 | 11 | 31 | | 2011 | 9 | 9 | 18 | | 2012 | 17 | 11 | 28 | | 2013 | 26 | 11 | 37 | | 2014 | 23 | 14 | 37 | | 2015 | 22 | 12 | 34 | | 2016 | 19 | 17 | 36 | | 2017 | 15 | 11 | 26 | | 2018 | 30 | 19 | 49 | | 2019 | 27 | 19 | 46 | | 2020 | 10 | 10 | 20 | | 2021 | 12 | 14 | 26 | | 2022 | 7 | 27 | 34 | | 2023 | 0 | 25 | 25 | | 2024 | 6 | 18 | 24 | | 2025 | 16 | 6 | 22 | | 2026 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Protein Kinase Inhibitors" by people in Profiles.
-
Waliany S, Cooper AJ, Liu SV, Gautschi O, Rotow JK, Smith KER, Weber UM, Lee DH, Loong HHF, Patel JD, Pennell NA, Nagasaka M, Patel SA, Tan DSW, Solomon BJ, Kim TM, Pall G, Riess JW, Sun L, Früh M, Uy NF, Gadgeel S, Feng J, Do A, Falcon C, Leighl NB, Baik CS, Lai GGY, Ou SI, Cheung KSY, Patil T, Mansfield AS, Weiler D, Yeap BY, Wirth LJ, Gainor JF, Drilon A, Lin JJ. Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium. Clin Cancer Res. 2026 Mar 16; 32(6):1157-1168.
-
Shah NJ, Sura S, Shinde R, Dai W, Wentworth C, Conkling P, Bupathi M, Vickery D, Perini R, Motzer RJ. Real-world treatment patterns and clinical outcomes among patients with metastatic renal cell carcinoma post immune-oncology and vascular endothelial growth factor receptor targeted therapies: A multicenter community oncology-based study. Urol Oncol. 2026 Apr; 44(4):110979.
-
Sine CC, Watts LP, Fernandez B, Marikar N, Wang J, Knudsen ES, Witkiewicz AK, Spencer SL. p16 expression confers sensitivity to CDK2 inhibitors in cyclin E1-driven ovarian cancers. Sci Signal. 2025 Nov 25; 18(914):eadv0415.
-
Waliany S, Roy SG, Pecci F, Weber UM, Sun F, Arter Z, Lomibao M, Alessi JV, Nishino M, Luo F, Repetto M, Falcon C, Do A, Peterson J, Liang J, Liu A, Nagasaka M, Ricciuti B, Drilon A, Ou SI, Neal JW, Patil T, Awad M, Yeap BY, Digumarthy SR, Lin JJ. Efficacy and Safety of Continuing Next-Generation ALK TKIs With Chemotherapy for Advanced ALK-Positive NSCLC: A Multicenter Retrospective Study. J Natl Compr Canc Netw. 2025 Nov 19; 23(12):522-530.
-
Molina-Cerrillo J, Roviello G, Bourlon MT, Studentova H, Fiala O, Cerbone L, Kucharz J, Ansari J, Zeppellini A, Taha T, Buti S, Ürün Y, Scagliarini S, Li H, Sunela K, Park SH, Rizzo M, Zgura A, Chiari R, Seront E, Catalano M, Ghosn M, Filosa A, Soares A, Massari F, Monteiro FSM, Grande E, Porta C, Bracarda S, Santoni M. Toxicity-related immunotherapy discontinuation and outcome in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1 study). Int J Cancer. 2026 Mar 01; 158(5):1396-1405.
-
Strong Caldwell A, Milner DC, Mehta NB, Marin AI, Gill ZS, Manoharan N. MERTK INHIBITOR-ASSOCIATED RETINAL TOXICITY IN A HUMAN. Retin Cases Brief Rep. 2025 Nov 01; 19(6):807-810.
-
Baird RD, Bermejo de Las Heras B, Ruiz-Borrego M, Vaklavas C, Moreno I, Oliveira M, Armstrong A, Turner N, Incorvati J, Twelves C, Ciruelos E, Hamilton E, Patel MR, Kabos P, Ciardullo C, Klinowska T, Lindemann JPO, Mathewson AM, Morrow CJ, Sykes A, Yang J, Zhang B, Victoria I. Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2- Advanced Breast Cancer: Results from SERENA-1. Clin Cancer Res. 2025 Oct 15; 31(20):4244-4254.
-
Wu BCB, Cheng L, Chanes N, Carroll AM, Aftab M, Bayer KU, Reece TB. Calcium/calmodulin-dependent protein kinase II inhibition using tatCN19o ameliorates spinal cord ischemia associated with aortic surgery. J Thorac Cardiovasc Surg. 2026 02; 171(2):476-485.
-
Nguyen VT, Chandler C, Strang JE, Astridge DD, Reigan P. RiSKs in Computational Modeling of Isoform-Selective RSK Inhibitors. J Chem Inf Model. 2025 Aug 25; 65(16):8411-8425.
-
Tiago M, Purwin TJ, Stefanski CD, da Silva RO, Fane ME, Chhabra Y, Haj JI, Teh JL, Kadamb R, Cai W, Rosenbaum SR, Chua V, Hacohen N, Davies MA, Villanueva J, Chervoneva I, Weeraratna AT, Erkes DA, Capparelli C, Aguirre-Ghiso JA, Aplin AE. Elevated NR2F1 underlies the persistence of invasive disease after treatment of BRAF-mutant melanoma. J Clin Invest. 2025 Sep 16; 135(18).
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|